DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zwvbgf/metastatic) has announced the addition of the "Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
- The report reviews key pipeline products under the drug profile section, which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Adenocarcinoma of The Pancreas and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating to pipeline products
Companies Involved in Therapeutics Development
- Gilead Sciences, Inc.
- MediGene AG
- Nanotherapeutics, Inc.
- Novartis AG
- Aduro BioTech, Inc.
- Halozyme Therapeutics, Inc.
- Oncolytics Biotech Inc.
- Peregrine Pharmaceuticals, Inc.
- Threshold Pharmaceuticals, Inc.
- Axcentua Pharmaceuticals AB
- BioCancell Therapeutics, Inc.
- NewLink Genetics Corporation
- Eleison Pharmaceuticals, Inc.
Drug Profiles
- glufosfamide
- TH-302
- MEK-162
- pelareorep
- BC-819
- paclitaxel liposomal
- Triapine
- luminespib
- CRS-207
- simtuzumab
- PEGPH-20
- AXP-10711
- erismodegib
- indoximod
- Stem Cell Therapy for Metastatic Adenocarcinomas
- siG-12D LODER
- PRI-724
- Anti-Angiogenesis Agent 2C3
For more information visit http://www.researchandmarkets.com/research/zwvbgf/metastatic.
